Call for Abstracts

General Information

Abstract submission open: 1st April 2024
Abstract submission deadline: 26th June 2024, 21:00 Central European Time

Abstracts submitted after the stipulated deadline will not be considered. Authors are strongly advised to submit prior to the deadline and avoid unnecessary delays which may affect the standing of their abstract.

In case of any abstract related queries please contact: alina.istrate@eortc.org.

Abstract Policy and Regulations

Abstracts on case studies will be rejected.

With the submission of an abstract to 36th EORTC–NCI–AACR symposium, the presenting author:

- Certifies to be an investigator with substantial involvement in the clinical study presented in the abstract.
- Accepts responsibility for the accuracy of the submitted abstract.
- Accepts to be the contact person for all correspondence regarding the abstract and inform co-authors of its status.
- Confirms that all co-authors are aware of and agree to the content of the abstract and support the data presented.
- Warrants that the data and conclusions presented in the abstract have not been presented or published at any meeting of 500 delegates or more prior to the 36th EORTC–NCI–AACR symposium.
- Agrees to submit updated data for important large studies presented (in part) at previous meetings. Violation of this policy may result in rejection of the submitted abstract.
- Certifies that the information in the abstract is for exclusive presentation in 36th EORTC–NCI–AACR symposium.
States that for all studies involving human or animal subjects, permission has been obtained from the relevant regulatory authority and informed consent given where appropriate.

For abstracts containing clinical trial data include: Trial abbreviation; Trial Registry Number or ID background; Objective, Design, Population studied (including sample size), Intervention, Outcome measure(s), Analysis, Trial status, Trial sponsor(s).

Identifies, obtains, and discloses any financial interest in products or processes described in the abstract for all abstract authors. This includes stock ownership, membership on an advisory board or board of directors, corporate-sponsored research, and other substantive relationships.

Agrees that the copyright of the abstract(s) is transferred to the European Journal of Cancer (EJC), where there will be printed in the abstract book, a supplement EJC.

Agrees that the abstract (s) are published on the 36th EORTC-NCI-AACR symposium website.

Trials in Progress abstracts will not be accepted.

Encore abstracts will be accepted if there is new data added/being presented. We will not accept the exact same abstract already presented at a different conference.

Abstract Preparation and Submission

Abstracts must be submitted in good English and carefully proofread to ensure the accuracy of published material. The Scientific Committee reserves the right to reject abstracts submitted in poor English or may request an immediate revision by the author.

Authors may provide their preference of presentation format: oral or poster.

Please choose one main topic to categorise. The Scientific Committee has the authority to re-categorise the abstract.

The title of the abstract should be concise and accurately describe the study undertaken. Do not use non-standard abbreviations and commercial names (generic names only).

Abstracts should be structured to include the following 4 sections:

- **Background**: introductory sentence specifying the purpose of the study.
- **Material and methods**: brief description of relevant experimental procedures.
- **Results**: summary of the results of the investigation.
- **Conclusions**: a statement of the main conclusions.

The abstract submission system will not accept abstracts that exceed 2900 characters (including body of the abstract, spaces and one table).
• **Only one data table** is permitted in the body of the abstract. Illustrations and figures are not allowed and will be deleted if submitted except for structure formula (see below).

• Accept chemistry focused abstracts on new agents should show the structure formula.

• **No references** should be provided.

• **Abbreviations** may be used if standard or if spelled out and defined at the first use (put in parentheses immediately after the first mention of a term or phrase). Compounds should be mentioned with the generic name, in lower cases. Commercial names are admitted in the text, with an ®, and if in brackets following the generic name, i.e. “generic (Commercial ®)”.

• Up to 3 **keywords** should be provided to distinguish the abstract for indexing purposes.

• **No more than 20 authors** can be listed with only their institutional affiliation(s), city and country. Mailing addresses and academic degrees should not be mentioned. For co-operative study groups, the name of the group should be used instead of individual institutional affiliations or include the name of the group in the title of the abstract.

• **Conflict of Interest**

  The conflict-of-interest policy requirements applies to all abstract authors. Any potential conflict of interest must be indicated online upon abstract submission. It is the responsibility of the Presenting Author to obtain disclosure information from all co-authors and to provide disclosure of all interests and relationships. These declarations will be made publicly available, on the symposium website.

• An e-mail confirming **receipt of the abstract** submitted online will be sent to the presenting author within 48 hours. An **abstract number** will be allocated and should be mentioned for any queries relating to the submitted abstract.

**Data Protection and sharing of contact details**

This event is organised by EORTC in collaboration with the Organisers.

To manage Participant’s registration, abstract submission, and participation to this event, EORTC and the Organisers collect and store Participant’s personal data in order to promote and evaluate the event, and to produce statistics on participation to the events. Other personal information might be required in scope of organisation of travel and accommodation. Your personal data may be collected through forms we ask you to complete or through the website of EORTC, the Organisers or their partners and subcontractors. This can create opportunities that undertakings that have nothing to do
with EORTC or Organisers might use for phishing emails purposes; please be careful not to provide your personal data to these undertakings or in case of doubts, please do not hesitate to verify the validity of the request with the EORTC. Our legal basis for the processing of the Participant’s data is contract execution (Participant’s registration to our event, organisation of the travel and accommodation and abstract submission processing), legal compliance (e.g. accountancy) and legitimate interest (statistics of participation, evaluation of the event and event promotion). Please note that when processing is based on legitimate interest, you will still be able to exercise the right to object. Participant’s name, specialty when relevant, organisation and country will appear on the event badges. The processing of personal data collected falls under the EU General Data Protection Regulation 679/2016 (hereafter also “GDPR”, applicable as of 25/05/2018) and the Belgian Law of 30 July 2018 on the protection of natural persons with regard to the processing of personal data.

Participant’s data will be stored for a maximum of 10 years after the end of the event. After this period, EORTC will either anonymise or delete Participant’s personal information.

Please also read carefully the EORTC Privacy Policy to find out more about privacy and your data subject rights.

If Participants register for this event, and if consented (optional), EORTC may contact Participants occasionally to inform them about other EORTC events that may be of interest or provide them with more information about EORTC activities or other relevant information relative to cancer research, for example in the form of a newsletter. If Participants do not wish to receive information from EORTC in the future, and want to be removed from EORTC’s mailing list, they can unsubscribe from the mailing list, or write at any time to events@eortc.org.

This event may include a photographer and may be recorded for promotional purposes only. These photos/recordings may be used in official EORTC press releases, printed and/or online publicity and published on any EORTC social media network, such as Facebook, Twitter, YouTube, or LinkedIn. EORTC will delete them after they are no longer needed for publicity purposes. To be removed from any EORTC online or offline publication please contact events@eortc.org.

Abstract Selection Process

Abstracts submitted for presentation in the 36th EORTC-NCI-AACR symposium will be reviewed by an international panel of experts in the field of the subject and will be judged
solely on the data submitted. The final decision on the presentation format of all selected 
abstracts lies at the sole discretion of the Scientific Committee.

The following presentation formats are applicable:

**Oral presentation**
The abstract is selected for oral presentation in one of the Plenary Sessions. Abstracts of 
superior quality can be selected for presentation in a session where discussants will place 
the research findings into perspective.

**Poster Presentation**
Abstracts that have been selected for poster presentation will be displayed on poster 
boards in a prominent poster viewing area. The posters will be grouped by topic and 
displayed for one day. A specific time will be devoted to poster viewing to ensure delegates 
have sufficient opportunity to acquaint themselves with the presented data.

**Poster Spotlight Sessions**
The Scientific Committee will make a special selection of posters which will be highlighted 
through short oral presentations followed by moderated discussion. These sessions will 
facilitate dynamic exchange on selected findings of broad interest.

**Registration**
Submitting an abstract for presentation in the 36th EORTC–NCI–AACR symposium does not 
constitute registration for the conference. When selected, abstract presenters must register 
to attend the 36th EORTC–NCI–AACR symposium in Barcelona.

The presenting author will receive the result of the review and the Scientific Committee’s 
decision on their abstract by email at the latest by end August 2024.

**Abstract Withdrawal**
EORTC cannot guarantee any request for withdrawal of an abstract that in any way delays 
the publications. Requests to withdraw abstracts will be accepted until 9 September 2024. 
After this date, abstracts selected for presentation must be presented. If the presenting 
author of a selected abstract cannot attend, they should assign a replacement and inform 
ENA 2022 secretariat of the replacement as soon as possible.
**Abstract Topics**

<table>
<thead>
<tr>
<th>Topic</th>
<th>Details</th>
</tr>
</thead>
<tbody>
<tr>
<td>Angiogenesis and vascular disrupting agents</td>
<td></td>
</tr>
<tr>
<td>Animal Models</td>
<td></td>
</tr>
<tr>
<td>Antibody–drug conjugates</td>
<td></td>
</tr>
<tr>
<td>Apoptosis inducers</td>
<td></td>
</tr>
<tr>
<td>Artificial Intelligence</td>
<td></td>
</tr>
<tr>
<td>Biomarkers Assays</td>
<td></td>
</tr>
<tr>
<td>Cancer Genomics</td>
<td></td>
</tr>
<tr>
<td>Cellular Therapies</td>
<td></td>
</tr>
<tr>
<td>Chemoprevention</td>
<td></td>
</tr>
<tr>
<td>Combination therapies</td>
<td></td>
</tr>
<tr>
<td>Combinatorial Chemistry</td>
<td></td>
</tr>
<tr>
<td>Cytotoxics (including Antimetabolites, Anthracyclin, Alkylating agents, Aurora kinases, Polo-like kinase, Topoisomerase inhibitors, Tubulin-binding compounds)</td>
<td></td>
</tr>
<tr>
<td>DNA Repair Modulation (e.g. PARP, CHK, ATR, ATM)</td>
<td></td>
</tr>
<tr>
<td>Drug Delivery</td>
<td></td>
</tr>
<tr>
<td>Drug Design</td>
<td></td>
</tr>
<tr>
<td>Drug Resistance and Modifiers</td>
<td></td>
</tr>
<tr>
<td>Drug Screening</td>
<td></td>
</tr>
<tr>
<td>Epigenetic modulators (HDAC Bromodomain modulators, EZH2)</td>
<td></td>
</tr>
<tr>
<td>Functional Genomics</td>
<td></td>
</tr>
<tr>
<td>Immune checkpoints</td>
<td></td>
</tr>
<tr>
<td>Molecular profiling</td>
<td></td>
</tr>
<tr>
<td>Molecular Targeted Agents</td>
<td></td>
</tr>
<tr>
<td>New agents for paediatric oncology</td>
<td></td>
</tr>
<tr>
<td>New drugs</td>
<td></td>
</tr>
<tr>
<td>New therapies in immuno-oncology</td>
<td></td>
</tr>
<tr>
<td>Novel clinical trial design</td>
<td></td>
</tr>
<tr>
<td>Oncolytic viruses and vaccination</td>
<td></td>
</tr>
<tr>
<td>Preclinical Models</td>
<td></td>
</tr>
<tr>
<td>Radiation Interactive Agents</td>
<td></td>
</tr>
<tr>
<td>Regulatory Affairs</td>
<td></td>
</tr>
<tr>
<td>Translational Studies</td>
<td></td>
</tr>
<tr>
<td>Tumour immunology and inflammation</td>
<td></td>
</tr>
<tr>
<td>Vaccines</td>
<td></td>
</tr>
</tbody>
</table>
Embargo Policy

Late-Breaking, Oral and Media selected abstracts for the 36th EORTC–NCI–AACR symposium (ENA 2024) are embargoed until the day of the presentation.

Information contained in the abstract as well as additional data and information to be presented must not be made public before the abstract has been presented at the 36th EORTC–NCI–AACR symposium.

The first author and co-authors must not release the research/study to news media.

If the policy is violated, the abstract will be automatically withdrawn from presentation and publication online.